Details of the Drug Reposition

General Information of This Drug (ID: DMMF8U0)

Drug Name
Atezolizumab   DMMF8U0
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DISI0V1B 2C25 Approved [1]
------------------------------------------------------------------------------------
8 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Squamous cell carcinoma DISQVIFL 2B60-2D01 Phase 3 [2]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 3 [2]
Breast cancer DIS7DPX1 2C60-2C65 Phase 3 [2]
Ovarian cancer DISZJHAP 2C73 Phase 3 [2]
Prostate cancer DISF190Y 2C82.0 Phase 3 [2]
Renal cell carcinoma DISQZ2X8 2C90 Phase 3 [2]
Urothelial carcinoma DISRTNTN 2C92.0 Phase 3 [2]
Bladder cancer DISUHNM0 2C94 Phase 3 [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
10 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [3]
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [2]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [2]
Follicular lymphoma DISVEUR6 2A80 Phase 1 [2]
Multiple myeloma DISEWP9B 2A83 Phase 1 [2]
Haematological malignancy DISCDP7W 2B33.Y Phase 1 [2]
Gastric adenocarcinoma DISWWLTC 2B72 Phase 1 [2]
Colorectal cancer DISNH7P9 2B91.Z Phase 1 [2]
Pancreatic cancer DISJC981 2C10 Phase 1 [2]
Melanoma DIS1RRCY 2C30 Phase 1 [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Indications(s)
1 Phase 0 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ulcer DISHF2X6 CA02-CB40 Phase 0 [5]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Transitional cell carcinoma DISWVVDR N.A. Investigative [6]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
6 Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma. Int J Dermatol. 2018 Oct;57(10):e90-e92.